AB0212 NON-ADHERENCE IN RHEUMATOLOGIC IMMUNE-MEDIATED DISEASES

Background: Patient adherence is a key determinant of treatment success in rheumatologic immune-mediated diseases. Available data about to biological treatments and factors associated non-adherence limited Spain. Moreover, no studies compare between subcutaneous oral drugs. Objectives: To evaluate prescribed biologicals drugs patients with diseases assess possible predictor non-adherence. Methods: Retrospective observational study including all for from 2017 2019 the outpatient pharmaceutical care area tertiary university hospital. Non-adherence was evaluated by reviewing scheduled drug-dispensing visits computerized application. We considered non-adherent every time that patient missed at least one drug administration. Data collected: demographic, total patient-treatments, dispensing route administration dispensed visit. classified adherent considering visits. Non-adherent group: number visits, reasons non-adherence, administrations per Results: 783 included: 52.4(13.7) years; 427(54.5%) female; 164 (20.9%) smoker; 697 (89%) Caucasian. A 79 (10.1%) received more than treatment. 869 patient-treatments: 294 adalimumab (33.8%), 236 etanercept (27.2%), 78 golimumab (8.9%), 47 apremilast (5.4%), 39 certolizumab (4.5%), 34 secukinumab (3.9%), 30 tocilizumab (3.5%). 9,197 Route administration: 6,406 (93.2%), 374 (6.8%). analysis: 2417 (26.3%) non-adherence/ visits: 92 unjustified (97.5%), 33 infection (1.4%), 18 (surgery) 0.7%, 3 pregnancy (0.1%), 6 others (0.3%). Number administrations/patient treatment: 675 (77.7%).Mean 2.5 (±12.9) administrations. administrations/drug: 9.9 baricitinib (±20.8), 15.8 tofacitinib (±31.2), 25.4 (±53.2). Predictor non-adherence: ethnicity (p=0.015), (p=0.006), (p=0.036). Age (p=0.072). Conclusion: - occurred 77.7% Demographic such as well treatment, despite their different frequency administration, were predictors did not influence Disclosure Interests: None declared